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Case presentation
A 58-year-old female was referred with complaints of progressive
weakness of the lower extremities for more than 4 years, and weakness
of the upper extremities, especially on abduction, over 6 months. She
had been evaluated at a local hospital, but no specific neurologic
condition was identified; she was referred for further study.
The patient had a history of pulmonary tuberculosis that had been
treated with a satisfactory regimen. The possibility of recurrence of
tuberculosis previously had been considered, and she had been treated
with rifampin, 300 mg, twice daily, and ethambutol, 400 mg, twice daily.
The physical examination was unremarkable. A history of intermittent
diarrhea and weight loss of 60 pounds over 4 years was elicited.
On admission, the laboratory values were: hemoglobin, 10.0 g/dl,
with normocytic, normochromic red cell indices and red cell anisocy-
tosis; sedimentation rate, 57 mm in the first hour; serum iron, 41 zg/dl;
total iron binding capacity, 223 g/dl; serum calcium, 8.4 mg/dl;
phosphorus, 3.1 mg/dl; serum albumin, 3.7 g/dl; alkaline phosphatase,
1383 lU/liter, with isoenzymes revealing predominantly bone fraction;
immunoreactive parathyroid hormone (PTH) (using a carboxyterminal
assay), 85 sL equivalents/mi (elevated), 25-hydroxyvitamin D concen-
tration, undetectable (normal, 10—40 nglml); 1,25-dihydroxyvitamin D
<5 pg/mI (normal, 20—60 pg/mi); and serum carotene, 30 g/di (normal,
48—200 g/dl). Blood urea was 15 mg/dl (normal 13—45 mg/dl) and serum
creatinine was 0.6 mg/dl (normal 0.6—0.9 mg/dl). The serum sodium
concentration was 144 mEq/liter; potassium, 4.2 mEq/liter; chloride,
116 mEq/liter; and bicarbonate, 20 mEq/liter. Arterial blood gases (on
room air) were: pH, 7.29; Pa02, 80 mm Hg; PaCO2, 37 mm Hg; and
calculated bicarbonate, 18 mEq/liter. Urinalysis disclosed: pH, 7.0;
trace protein and otherwise unremarkable. A 24-hr urine collection
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contained 100 mg of calcium. Radiographs revealed coarsening of
trabeculations and pseudofractures of the pubic rami.
Discussion
DR. RAJIV KUMAR (Chairman, Division of Nephrology,
Mayo Clinic, and Ruth and Vernon Taylor Professor, Professor
of Medicine, Biochemistry, and Molecular Biology, Mayo Med-
ical School, Rochester, Minnesota): The patient is a 58-year-old
woman with proximal limb muscle weakness and intermittent
diarrhea for 4 years, hypocalcemia, borderline hypophos-
phatemia, an increased immunoreactive PTH concentration,
undetectable vitamin D metabolites, a non-anion gap metabolic
acidosis with perhaps inadequate respiratory adaptation, and
radiologic evidence of osteomalacia. At the time of her initial
visit, she was being treated with rifampin. For the purposes of
this discussion, let us make the reasonable assumption that the
patient has osteomalacia. How did she develop this condition,
and what do we know about the physiology of calcium absorp-
tion and excretion that might shed some light on the develop-
ment of osteomalacia in this patient? I will first review normal
calcium handing by the normal human and then will discuss the
formation of vitamin D, new information on the role of vitamin
D in the induction of calcium-binding proteins, and the interac-
tion of such calcium-binding proteins with the plasma mem-
brane calcium pump. In my discussion, I will point out how
abnormalities in the integrated calcium-vitamin D systems
might have accounted for the disorder seen in this patient.
Normal calcium metabolism
Under normal circumstances, an adult human ingests approx-
imately 1000 mg of elemental calcium per day; 800—900 mg of
calcium appear in the feces [1]. Of the ingested calcium,
approximately 400—500 mg are absorbed, but approximately 300
mg are secreted via intestinal secretions, pancreatic secretions,
and bile into the intestinal tract. Thus, net absorption of calcium
into the extracellular fluid is approximately 100—200 mg per day.
Extracellular fluid calcium equilibrates between the extracellu-
lar fluid pool and the intracellular and bone pools; the latter
includes a rapidly exchangeable bone pool and a more stable
bone mineral pool. Plasma calcium is filtered at the glomerulus
and, following reabsorption of a considerable amount, approx-
imately 100—200 mg (or the amount reflecting net absorption
from the intestinal tract) appear in the urine daily in the patient
in a steady state of calcium balance. In the final analysis, total
body calcium balance depends on the absorption of calcium
from the intestinal tract and its excretion by the kidney.
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Vitamin D plays a critical role in the adaptation of the body to
decreases in calcium availability. More than 50 years ago,
Nicolaysen and others conclusively demonstrated a role for the
vitamin in increasing calcium absorption from the intestine
[2—7]; even earlier work had shown increased fecal calcium loss
in vitamin D-deficient, rachitic children [8—12]. The absorption
of calcium by the intestinal mucosa requires the expenditure of
energy because it occurs against a chemical and electrical
gradient [2, 13—24]. The movement of the ion into the cell from
the intestinal lumen does not require the expenditure of energy
because it occurs down an electrochemical gradient. At the
basolateral portion of the intestinal cell, however, the move-
ment of calcium from within the cell into the extracellular fluid
space occurs against an electrochemical gradient; hence the
need for the expenditure of energy. Vitamin D plays a role in
both of these processes. Excellent evidence demonstrates that
calcium movement into the cell through the apical brush-border
membrane is facilitated by vitamin D via its active metabolite,
1,25-dihydroxyvitamin D3 [2, 13—241. Calcium movement
across the cytosol of the intestinal cell is enhanced by the
vitamin D-induced protein, calcium-binding protein [13]; in
addition, the vitamin increases the rate of extrusion of Ca2
from within the cell into the extracellular fluid space [13, 16].
The physiologic mechanisms that come into play to maintain
normal plasma calcium concentrations involve a complex inter-
action between parathyroid hormone (PTH) and vitamin D (Fig.
1). If the plasma calcium concentration is diminished due to any
cause, increased amounts of PTH are released into the circula-
tion [14—24]. Parathyroid hormone increases the mobilization of
bone and soft-tissue calcium and also decreases the fractional
excretion of calcium by the kidney. In addition, PTH stimulates
the renal enzyme 25-hydroxyvitamin D3-la-hydroxylase, thus
stimulating the synthesis of 1,25-dihydroxyvitamin D3. This
latter substance increases the intestinal absorption of calcium
and thereby helps bring plasma calcium concentration back
toward normal.
Conversely, in hypercalcemia, PTH release decreases, and
the release of calcitonin is stimulated. A sequence of events that
is the converse of that occurring in hypocalcemic states is
brought into play. It is important to remember that adaptations
to alterations in plasma calcium concentrations involve the
secretion of increased or decreased amounts of PTH that, in
turn, alter the renal synthesis of 1,25-dihydroxyvitamin D3.
Although the synthesis of I ,25-dihydroxyvitamin D3 does in-
crease somewhat in hypocalcemic situations even in the ab-
sence of PTH, this change is modest, and it is very likely that
the major factor contributing to the altered synthesis of 1,25-
dihydroxyvitamin D3 in hypo- or hypercalcemia is the change in
the plasma concentration of PTH.
The physiologic changes that occur in hyper- or hypophos-
phatemic states are somewhat different than those occurring in
states of hypo- or hypercalcemia [14-191 (Fig. 2). If the plasma
phosphorus concentration increases, for example, as a result of
increased retention of phosphate by the failing kidneys, there is
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a reciprocal decrease in plasma calcium concentrations. This
decrease in turn stimulates PTH release, and the renal excretion
of phosphate increases. Increased plasma phosphate concentra-
tions also decrease the activity of the 25-hydroxyvitamin D3-
la-hydroxylase by an unknown mechanism. This enzyme inhi-
bition in turn results in decreased circulating concentrations of
1,25-dihydroxyvitamin D3. Decreased intestinal absorption of
phosphate and a decrease in the mobilization of bone and
soft-tissue phosphate occur as a result. Conversely, when
plasma phosphate concentrations are diminished, renal excre-
tion of phosphate decreases as a result of PTH-dependent as
well as PTH-independent mechanisms. Low plasma phosphate
concentrations, by a PTH-independent mechanism, stimulate
the renal 25-hydroxyvitamin D3-la-hydroxylase enzyme. The
resulting increased synthesis of 1 ,25-dihydroxyvitamin D3 in
turn increases the absorption of phosphate from the intestine.
In addition, more phosphate is mobilized from bone. I would
emphasize that adaptations in the vitamin D endocrine system
that occur in response to alterations in plasma phosphate
concentration are independent of PTH.
The formation of vitamin D and its metabolism to active
metabolites
Vitamin D is not a vitamin in the strict sense of the word
inasmuch as it is formed endogenously in sufficient quantities
following exposure of an individual to adequate amounts of
sunlight [20—221 (Fig. 3). However, inadequate exposure to
sunlight that has accompanied our way of living has resulted in
Fig. 4. The formation of
/ ,25-dihydroxyvitamin D3.
the cholecalciferols becoming de facto vitamins. As is well
known, vitamin D1 is formed in the skin from a precursor,
7-dehydrocholesterol, a byproduct in the synthesis of choles-
terol. Under the influence of ultraviolet light, the B-ring of
7-dehydrocholesterol is opened to form previtamin D3, which
undergoes thermal equilibration to form vitamin D3 [25—38].
Vitamin D3 is transported out of the skin, perhaps in association
with vitamin-D-binding protein (a member of the a-fetoprotein-
albumin super-family of proteins) to the liver, where it under-
goes conversion to 25-hydroxyvitamin D3 both in hepatic
microsomes and hepatic mitochondria [38—41] (Fig. 4). The
microsomal enzyme is operative under normal physiologic
circumstances, whereas the mitochondrial enzyme probably
plays a role when large amounts of vitamin D3 are present in the
circulation. The Km for the microsomal enzyme is lower than
that for the mitochondrial enzyme, and the activity of the
microsomal enzyme is negatively regulated by the amount of
25-hydroxyvitamin D3 present in plasma. Because the mito-
chondrial enzyme is not closely regulated, however, large
amounts of vitamin D3 are converted to 25-hydroxyvitamin D3
in some situations (for example, vitamin D toxicity). The
microsomal vitamin D1 25-hydroxylase enzyme is a cytochrome
P-450-like enzyme that consists of a flavo-protein and a cy-
tochrome P-450 that utilizes oxygen to convert vitamin D3 to
25-hydroxyvitamin D3 [20, 42]. The activity of this enzyme is
diminished by drugs such as isoniazid [43]. Other cytochrome
P-450s that are induced by phenytoin, phenobarbital, and
rifampin decrease concentrations of the substrate, vitamin D3,
7-dehydrocholesterol Pre-vitamin D3 Vitamin D3
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by accelerating its metabolism to other, inactive compounds
[44—49]. The major circulating metabolite of vitamin D3, 25-
hydroxyvitamin D3 is biologically inert in physiologic amounts.
When concentrations of 25-hydroxyvitamin D3 are high, as in
hyper-vitaminosis D, 25-hydroxyvitamin D3 can be converted
to other biologically active compounds such as 5,6 trans 25-
hydroxyvitamin D3 [50]. The intrinsic, albeit low, affinity of
25-hydroxyvitamin D3 for the 1,25-dihydroxyvitamin D3 recep-
tor and the formation of 5,6 trans 25-hydroxyvitamin D1 could
account for the biologic activity of large, pharmacologic
amounts of vitamin D3 or 25-hydroxyvitamin D3 in patients with
renal failure and hypoparathyroidism in whom the 25-hydroxy-
vitamin D3-la-hydroxylase enzyme activity is low or absent.
Under physiologic circumstances, 25-hydroxyvitamin D3 is
converted in the mitochondria of the renal proximal tubule to
1,25-dihydroxyvitamin D3, the biologically active form of the
vitamin [16—18, 20—24, 51—65] (Fig. 4). As might be predicted,
the conversion of 25-hydroxyvitamin D3 to 1 ,25-dihydroxyvita-
mm D3 occurs in situations of calcium and phosphate demand.
When calcium and phosphate requirements have been met,
25-hydroxyvitamin D3 is converted to another metabolite,
24,25-dihydroxyvitamin D3, a metabolite of uncertain biologic
role [18]. The 25-hydroxyvitamin D3-lct-hydroxylase enzyme is
a multicomponent cytochrome P-450 complex. It comprises a
flavo-protein, an intermediate iron sulfur protein, and a P-450-
like enzyme that uses molecular oxygen to convert 25-hydroxy-
vitamin D3 to 1,25-dihydroxyvitamin D3 [60—65]. The activity of
this enzyme is influenced by a large number of factors. These
have been summarized in two exhaustive reviews [16, 66]. The
most important physiologic regulators are PTH and the concen-
tration of inorganic phosphate in the extracellular fluid. Other
hormones such as calcitonin and growth hormone, and other
ions such as Ca2 ion (direct effect rather than via PTH) and
hydrogen ion may play a role; their role, however, is secondary
to that played by PTH and inorganic phosphorus.
The metabolism of 1 ,25-dihydroxyvitamin D3 to other sterols
regulates its concentrations in various target tissues. It under-
goes side-chain oxidation to form an inert 23-carbon acid,
calcitroic acid [67—691 (Fig. 5). The process is not well regulated
and accounts for approximately 25% of the metabolism of
1,25-dihydroxyvitamin D3. Side-chain oxidation occurs in both
the liver and intestine and requires a la-hydroxylated substrate,
namely, 1,25-dihydroxyvitamin D3. Non-la-hydroxylated sub-
T112
hours
MCR
liter/day
PR
pg/day
l,25(OH),D1 —10 44.6 5.7 —1.5
24,25(OH)2D3 6.5 0.4 9.2 1.5 26.4 7.2
strates such as 25-hydroxyvitamin D3 cannot undergo side-
chain oxidation in anephric animals [67, 68]. Also, 1,25-dihy-
droxyvitamin D3 undergoes hydroxylation to 1,24,25-
trihydroxyvitamin D1, a metabolite with reduced bioactivity, in
target tissues such as the intestine, kidney, and cartilage
[70—73], In addition, other tissues that contain the 1,25-dihy-
droxyvitamin D3 receptor also have 25-hydroxyvitamin D3 or
l,25-dihydroxyvitamin D3 24-hydroxylase activity. Several
other metabolic processes involving modifications of the side
chain occur in target cells that convert 1,25-dihydroxyvitamin
D3 to other metabolites, such as I ,25,26-trihydroxyvitamin D3,
23-oxo- I ,25-dihydroxyvitamin D3, 23-oxo- 1 ,25,26-trihydroxy-
vitamin D3, and a 1,25-dihydroxyvitamin D3-23,26 lactone [16].
In general, these processes are induced by I ,25-dihydroxy-
vitamin D3. They occur in target tissues of the hormone and
result in metabolites with reduced biologic activity. They can be
thought of as processes that terminate the hormonal response,
thereby preventing toxicity. Because modifications of the side
chain result in metabolites that have reduced biologic activity,
it theoretically is possible to design metabolites of I ,25-dihy-
droxyvitamin D3 that have increased or prolonged biologic
activity by introducing groups into the side chain that block the
metabolism of the sterol. We recently synthesized an analogue,
26,27-dimethyl-l,25-dihydroxyvitamin D, which has increased
and more prolonged biologic activity than 1 ,25-dihydroxyvita-
mm D3 in vivo [74]. The enhanced bioactivity of this analogue
is not due to an increase in its affinity for the I ,25-dihydroxyvi-
tamin D3 receptor. Several similar analogues have been synthe-
sized; one of them, I ,25(OH)2-26--27-hexafluoro-vitamin D3,
displays increased biologic activity in vivo and in vitro (see
references in 74).
Various side-chain modification processes account for only a
fraction of the metabolism of the hormone (approximately 20%
1 .24,25-trihydroxyvitamin D3
24-oxo-1 ,25-dihydroxyvitamin D3
A-ring
monoglucuronide
2326-lactone
?23-oxo-1 ,25-dihy-
droxyvitamin D3
1,25-dihydroxyvitamin D3
Table 1. Metabolic clearance rates and production rates of
I ,25(OH)2D3 and 24,25(OH)2D3
Other polar
biliary metabolites
Calcitroic acid
1 ,25,26-trihy-
droxyvitamin D3
Fig. 5. The catabolism of 1,25-dihydroxyvitamin D3.
a T112, half-life; MCR, metabolic clearance rate; PR, production rate.
Values shown are mean s.
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onjugation
Fig. 6. The enterohepatic circulation of 1,25-dihyroxyvitamin LI3.
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Table 2. Alterations in the enterohepatic physiology of l,25(OH)2D3 in patients with cholestatic liver diseasea
Plasma concentrations
25(OH)D
(ng/ml)
I,25(OH)2D
(pg/mI)
24,25(OH)2D3
(ng/mI)
Ca
(mg/dl)
P04
(mg/dl)
iPTHL
Normal 17.5 1.2 46.1 4.5 1.6 0.2 9.5 0.3 3.5 0.5 30.9 9
Primary biliary cirrhosis 15.7 2.9 42.0 4.3 2.6 0.4 9.4 0.2 3.6 0.6 22.6 7.2
P NSb NS 0.05 NS NS <0.01
Radioactivity Bile Urine Feces
% Total administered (6 hours) (6 days) (6 days)
Normal (N = 5) 15.6 14 69
Primary biliary cirrhosis 5.7 27 26(N = 2)
a From Ref. 79.b NS, not significant.
to 30%). In addition other mechanisms, such as biliary excre-
tion of l,25-dihydroxyvitamin D3, also play an important role in
the metabolism of the hormone. Following the administration of
1 ,25-dihydroxyvitamin D3, the hormone rapidly clears from the
peripheral circulation [75, 76] (Table 1). This phenomenon is
associated with the rapid appearance of radiolabel in the bile of
animals and humans [77, 781. The metabolites that are excreted
in bile normally are reabsorbed in the proximal duodenum and
jejunum of animals and human subjects. Thus, there exists an
active enterohepatic circulation for 1 ,25-dihydroxyvitamin D3
metabolites (Fig. 6).
In certain forms of cholestatic liver disease, such as primary
biliary cirrhosis, the biliary excretion of 1 ,25-dihydroxyvitamin
D3 is altered and circulating concentrations of PTH are low
(Table 2). The retention of 1,25-dihyroxyvitamin D3 could cause
transiently elevated concentrations of the sterol; these would
cause transient hypercalcemia, thus suppressing PTH secre-
tion. The lower PTH concentrations would diminish the syn-
thesis of 1,25-dihyroxyvitamin D3. A new steady state (noted in
Table 2) would result. These changes could at least partly
account for the low-turnover bone disease in individuals with
primary biliary cirrhosis [79].
The biliary metabolites of 1,25-dihydroxyvitamin D3 are
much more polar than the native hormone. They are either
neutral or acidic metabolites; the acidic compounds behave like
glucuronides and sulfates on various chromatographic systems.
We have isolated in pure form one such biliary metabolite, an
A-ring glucuronide of 1 ,25-dihydroxyvitamin D3 [80]. We have
examined the biologic activities of various model glucuronides
and glucosides and have shown that these compounds are less
active than the native sterol [79]. They display biologic activity
as a result of hydrolysis in the intestine or other tissues of the
glucuronide or glucoside moiety from the aglycone. Further-
more, we have shown that they are biologically inactive in
systems that lack endogenous glucuronidase activity. The bil-
iary handling of l,25-dihydroxyvitamin D3 thus can be con-
ceived of as an excretory route for I ,25-dihydroxyvitamin D3,
as the metabolites in bile are less active than the native
hormone and because a large percentage of them are excreted
into the feces in an unaltered form. Some of these metabolites
can be reutilized after deconjugation in the intestine, as is
probably the case for the glucuronides. Disturbances in the
Table 3. Distribution of the vitamin D-dependent calcium-binding
proteins
Type of CaBP
9kD 28kD
Intestine + (rodent, bovine, ? human) + (avian, ? human)
Kidney + (mouse, bovine) + (rodent, human, avian)
Placenta + (rat, human) —
Shell gland — + (avian)
Pancreas + (porcine) + (human, avian)
Brain — + (rodent, human, avian)
Bone — + (avian)
Teeth — + (human, rodent)
Inner ear — + (human)
Visual cortex — + (feline)
enterohepatic circulation, as might occur in malabsorption
syndromes, could result in disease such as osteomalacia.
Vitamin D-induced calcium-binding proteins
The manner in which 1,25-dihydroxyvitamin D3 functions in
various tissues like the intestine or kidney, while not directly
relevant to the patient being discussed today, sheds light on the
regulation and mechanism of solute transport in various epithe-
ha and on the control of growth and cell differentiation. In the
intestine, 1,25-dihydroxyvitamin D3 increases the absorption of
calcium; it also increases the mobilization of soft tissue and
bone calcium [15—18, 20—24]. Further, 1,25 dihydroxyvitamin
D3 might play a direct role in mineralization, although this is a
matter of considerable debate [18]. Considerable evidence
indicates that 1 ,25-dihydroxyvitamin D3 alters the rate of cel-
lular growth and differentiation of several cell types; further, it
might have an immune modulatory role [18]. It acts both via
genomic and non-genomic mechanisms. In target tissues such
as the intestine, it combines with a nuclear receptor that
resembles receptors for thyroid hormone and other steroid
hormones [81—85]. The receptor comprises a hormone-binding
and a DNA-binding domain; the DNA-binding domain has
several "zinc fingers" that may directly associate with seg-
ments of DNA. Receptor mutations in individuals with vitamin
D-dependency rickets, type II, have helped define the physiol-
ogy of the vitamin D receptor and establish its important role in
the mechanism of action of 1 ,25-dihydroxyvitamin D3 [86]. In
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addition, considerable information suggests that I ,25-dihydroxy-
vitamin D3 also activates various non-genomic processes such
as inositol phospholipid metabolism. Although there is no
question that these phenomena occur, their precise role in the
mechanism of action of this sterol hormone remains to be
defined.
The hormone receptor domain, probably in association with
other factors, increases the transcriptional activity of RNA
polymerase II. Several genes are activated following the admin-
istration of 1,25-dihydroxyvitamin D3 [17—19]. The most notable
of the genes with increased activity is the calcium-binding
protein (CaBP) gene [19]. These proteins are present in calcium-
transporting tissues such as the intestine, the renal distal tubule,
and bone, as well as in other non-calcium-transporting tissues
such as the pancreas and brain [19, 87—92] (Table 3). Their
induction coincides with an increase in calcium transport, and
they appear to be induced by vitamin D but not calcium [2, 13],
In some tissues (for example, the brain), their amount does not
depend on the concentrations of vitamin D. In general, the
CaBPs can be classified into two general groups: a 28 kD CaBP
found in mammalian kidney, brain, and pancreas, and a 9 kD
CaBP found in the placenta and in mouse kidney [191. The latter
protein is also probably found in mammalian intestine. In avian
species, only a 28 kD CaBP exists in several tissues, including
the kidney, brain, intestine, chorioallantoic membrane, and
bone. In humans, a 28 kD CaBP is present in the distal tubule,
in the brain, particularly in cerebellar cells, and possibly in the
intestine, whereas the 9 kD CaBP is found in placenta and
intestine.
To determine the biologic function of various CaBPs, one
must determine how these proteins interact with calcium, what
interactions they might have with other enzymes responsible
for calcium transport, and whether they can increase the
movement of calcium across compartments in which they are
present. To do this, one needs to have some idea about the
structure of these proteins and their properties following inter-
actions with calcium. Many of the studies concerning CaBPs in
mammalian species—in humans in particular—have been ham-
pered by the low availability of these proteins and because they
are not easily purified. The chicken 28 kD CaBP and its brain
homologue in mammals, however, are more easily isolated than
are CaBPs from other tissues; these proteins are good models
for studying CaBP function, as they are virtually homologous
with other human and mammalian 28 kD CaBPs. Likewise, the
bovine 9 kD CaBP and the rat 9 kD CaBP from bovine or rat
intestine are good models for the human 9 kD CaBPs. To study
the structure of various CaBPs, we isolated the 9 kD CaBP from
bovine intestine, raised antibodies against it, and used these
antibodies to isolate a CaBP clone from a eDNA library
obtained from bovine intestine [91]. We found a high degree of
homology among the various mammalian 9 kDa CaBPs [91]. We
also isolated chick intestinal CaBP and determined its structure
using Edman degradation and mass spectrometry [921. We
found the amino acid sequence of chick intestinal CaBP to be
similar to the predicted sequence of chick intestinal CaBP
derived from the nucleotide sequence of a cDNA clone isolated
by Hunziker [90]. On examining the structure of these proteins,
it is clear that they contain EF-hand sequences, described
initially by Kretsinger as loop-helix-loop structures that bind
calcium to various oxygen-containing residues within the loop
Table 4. Calcium-transporting tissues in which vitamin D-dependent
calcium-binding proteins and the plasma membrane calcium pump are
present or co-localized
CaBP PM Ca2 Pumpa
Kidney, distal tubule (human, rat) + +
Kidney, other portions — —
Intestine (rat) +
Placenta (human, rat) + +
Osteoblast-like cells (human) — +
Choroid plexus — +
Shell gland + +
a PM, plasma membrane.
region of the protein 1931. The 28 kD CaBP has 6 EF-hand
structures, whereas the 9 kD CaBP has 2 EF hands. We studied
the 28 kD CaBP with terbium fluorescence spectroscopy to
determine the nature of the interaction between calcium and
this protein [941. Fluorescent lanthanides such as terbium
interact with proteins in a manner similar to that exhibited by
calcium; excitation of terbium bound to the protein by different
techniques in the presence or absence of calcium or other
lanthanides allows one to determine the manner in which
calcium binds to the protein and the relationship of different
calcium-binding sites to one another. Using lanthanide spec-
troscopy and excitation by direct or indirect methods, we
showed that the 28 kD CaBP bound between 3 and 4 moles of
terbium with high affinity, and that one of the moles of terbium
bound to a site that was close to a tryptophan residue. When we
performed calcium displacement studies, we observed at least
two classes of binding sites. Using circular dichroism studies,
we observed a conformational change in the protein when we
added calcium or EDTA. Similarly, intrinsic protein fluores-
cence studies demonstrated at least two classes of binding sites
in the protein. Therefore, the model that we propose for the
interaction of calcium with the 28 kD CaBP involves a two-step
binding sequence in which either one or two moles of calcium
bind to a high-affinity site, and another two moles bind to a
relatively lower-affinity site. Similar experiments have been
performed by several groups with the 9 kD CaBP demonstrating
a conformational change upon binding calcium.
As I noted earlier, the 28 kD CaBPs have 6 EF-hand binding
regions, whereas the protein appears to bind only 4 moles of
calcium, We attempted to resolve the apparent dichotomy
between the numbers of binding sites and the numbers of moles
of calcium bound by the protein. Two of the EF-hand domains
of CaBP, namely domain 2 and domain 6, are imperfect EF
hands. To study this further, we isolated from rat brain a 28 kD
CaBP in native form, and we screened a eDNA library from rat
brain for the presence of cDNA clones for the protein [95].
Analysis of the cDNA clones showed 6 EF hands. Using
site-directed mutagenesis, domain 2 and domain 6 were re-
moved from appropriate clones. Full-length and mutant pro-
teins then were expressed in large amounts in E. coil. Following
isolation of the proteins, we observed the binding of calcium
both to the full-length protein and to mutants lacking either one
or both EF hands as noted earlier. Thus, domains 2 and 6
probably are not important for calcium binding. What does all
this basic information mean clinically, and can we relate it to
human disease?
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CaBPs and the plasma membrane calcium pump
Based on its biophysical properties, it is clear that the 28 kD
CaBP has biophysical properties similar to those of calmodulin.
The importance of this observation lies in the fact that the
plasma membrane calcium pump, which extrudes calcium from
within the cell, is strongly stimulated by calmodulin. Several
groups have tried to determine whether CaBPs increase the
activity of the calcium pump. Unfortunately, the data until now
have not been clear; in general, most of the studies show that
CaBP, either bound to calcium or in the absence of calcium,
does not increase or stimulate calcium pump activity [96—103].
We have used histochemical techniques to determine
whether the CaBP protein and calcium pump might be part of a
common calcium transporting mechanism. To this end we have
co-localized these two antigens in calcium-transporting tissues
using immunohistochemistry [104—1101 (Table 4). In human
kidney, one finds the calcium pump present only in the baso-
lateral portion of the cells of the distal tubule. The calcium
pump co-localizes with CaBP in this segment of the nephron.
Similarly, rat distal tubule cells contain both the calcium pump
and CaBP. It is of interest to note that the intercalated cells of
the distal tubule in the rat kidney do not contain epitopes for
either of these proteins. Human osteoblast-like bone cells
contain calcium pump epitopes and, even though these partic-
ular cells do not contain CaBP, there is abundant evidence for
the presence of CaBP in bone. Human placenta contains the
calcium pump along the basal portion of the syncytiotropho-
blast of the placenta; work performed by other investigators has
shown that the 9 kD CaBP is present in these tissues as well
[88]. Similarly, rat duodenum contains substantial amounts of
CaBP in absorptive cells [89]. It is clear that CaBPs and calcium
pumps localize together in many tissues. These two proteins are
very likely part of a common calcium-transporting mechanism.
In the patient we are discussing today, several abnormalities
might have contributed to her osteomalacia. The malabsorption
was found to be secondary to bowel bacterial overgrowth. She
had malabsorption of dietary vitamin D because of steatorrhea.
In addition, she probably had increased fecal losses of 1,25-
dihydroxyvitamin D3 metabolites as a result of an interruption
of her enterohepatic circulation. All these problems resulted in
low vitamin D, low 25-hydroxyvitamin D, and low 1,25-dihy-
droxyvitamin D concentrations. Additionally, she was taking
rifampin, which is known to increase the metabolism of vitamin
D3 to other nonactive metabolites, thereby making less sub-
strate available for the formation of 25-hydroxyvitamin D3. Had
she been treated with isoniazid, she also might have had a
decrease in 25-hydroxyvitamin D concentration as a result of
suppression of the vitamin D3 25-hydroxylase enzyme. There
have been descriptions of acidosis affecting 1 ,25-dihydroxyvi-
tamin D3 concentrations [16], but acidosis is an unlikely culprit
in this particular instance because of its rather modest level.
Calcium malabsorption resulted in secondary hyperparathy-
roidism. She was treated with small amounts of exogenous
vitamin D3, supplemental calcium, and antibiotics. No evidence
of tuberculosis was found. Her bone disease resolved in several
weeks.
Questions and answers
DR. NIcoLAos E. MAD lAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): What
is our understanding of the mechanisms involved in the trans-
port of 1,25 dihydroxy vitamin D3 into the nucleus for binding to
its receptor and the subsequent induction of the calcium-
binding protein genes?
DR. KUMAR: Work is being done on the mechanism of action
of the 1,25 dihydroxyvitamin D receptor. The work falls into 2
general areas: One area of investigation has dealt with abnor-
malities that occur in patients who have inherited defects in the
structure of the vitamin D receptor. In essence, mutations
occur either in the 1,25 dihydroxyvitamin D3 binding domain or
in the DNA domain of the receptor; these mutations cause
abnormalities in the manner in which the receptor binds to
DNA [111—117]. Presumably, a lack of binding to DNA results
in a lack of transcription of CaBP. Less is known about a
second area of investigation, namely, how 1,25 dihydroxyvita-
mm D3 binds to its receptor and subsequently increases the
transcription of CaBP. Several investigators have examined the
5' regions of the CaBP gene and have been unable to find
1 ,25-dihydroxyvitamin D3-receptor specific promoter/enhancer
elements in the CaBP gene. Whether or not there are promoter!
enhancer elements in introns of the CaBP gene or in portions
distant from the gene has not been established as yet. Investi-
gators have examined the mechanism of 1,25 dihydroxyvitamin
D3 on the osteocalcin gene [118—120]. As you know, osteocalcin
is a protein formed by osteoblasts; its synthesis is increased by
1 ,25-dihydroxyvitamin D3. It appears that the interaction of
1 ,25-dihydroxyvitamin D3 and its receptor occurs at very spe-
cific regions (approximately 500—600 base pairs) upstream from
the transcription start site in the osteocalcin gene. Other genes
regulated by 1 ,25-dihydroxyvitamin D include the osteopontin
gene [121]; the same principles that have been observed for the
osteocalcin gene apply to the osteopontin gene.
DR. MADIAS: Is there any evidence that the induction of the
calcium-binding proteins by vitamin D is affected by variables
such as the age of the animal, and by its calcium, phosphorus,
and vitamin D status?
DR. KUMAR: That's an excellent question. There is a resis-
tance to 1 ,25-dihydroxyvitamin D3 in aging rats that appears to
be due to a decrease in the amount of 1 ,25-dihydroxyvitamin D3
receptor [122]. There are also age-related decreases in 1,25-
dihydroxyvitamin D3 concentrations that appear to be propor-
tional to decreases in GFR that occur with aging [123, 124]. The
decreases in 1,25-dihydroxyvitamin D3 production as well as
receptor concentrations might then cause a decrease in re-
sponse.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You mentioned
that a reduction in the enterohepatic circulation of bile in
patients with primary biliary cirrhosis, and perhaps in this
patient with diarrhea, can cause hypocalcemia. Are there any
diseases in which an associated increase in the enterohepatic
circulation in turn might account for some of the hypercalcemic
states?
DR. KUMAR: Not that I'm aware of.
DR. PAUL KURTIN (Director, Dialysis Unit, New England
Medical Center): You didn't mention the role of vitamin D in
the regulation of PTH. Would you please discuss that? Also, do
intravenous and oral vitamin D affect PTH regulation differ-
ently?
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DR. KUMAR: You're quite right; I neglected to mention that
there is good evidence that 1 ,25-dihydroxyvitamin D3 decreases
PTH synthesis and that receptors for I ,25-dihydroxyvitamin D3
are present in parathyroid glands [125, 126]; some evidence also
suggests that there might be fewer receptors in uremic animals
relative to normal animals [127, 128]. The role of intravenous
treatment in that regard relates to the fact that one can obtain
reproducibly high concentrations of 1 ,25-dihydroxyvitamin D3
in plasma and hence in parathyroid cells. This is dificult to do
when you give 1 ,25-dihydroxyvitamin D3 orally. That would
suggest that maybe there is a direct effect of I ,25-dihydroxyvi-
tamin D on the intestinal mucosa that increases calcium
absorption. Some data show that if you can get the 1,25-
dihydroxyvitamin D3 concentrations high enough by oral dos-
ing, you can indeed get suppresssion that might be equivalent to
that found with intravenous I ,25-dihydroxyvitamin D3 [129]. I
think it's fair to say that the reason intravenous I ,25-dihydroxy-
vitamin D3 works consistently is that one can get more 1,25-
dihydroxyvitamin D3 to where it is supposed to get to repro-
ducibly. I don't know of a lot of good data suggesting that the
oral form will cause more hypercalcernia because of its direct
effect on the mucosa.
DR. KURTIN: I have a question regarding some patients we
see in the dialysis unit and today's patient: is the myopathy
associated with vitamin D deficiency? Do muscle cells have
vitamin D receptors, and is the myopathy related to alterations
in calcium metabolism or to some other effect?
DR. KUMAR: Vitamin D metabolites have several effects on
muscle metabolism. A profound hypotonia has been described
in individuals who have nutritional vitamin D deficiencies that
disappears within a very short period after the administration of
vitamin D; the restoration of normal muscle tone is not related
to changes in the concentrations of various divalent ions. The
addition of 25-hydroxy D3 to the medium in which a diaphragm
is suspended increases the uptake of amino acids and the
amounts of amino acid incorporated into muscle protein [130].
These observations could explain alterations in muscle tone in
vitamin D deficiency. Others have demonstrated that 1,25-
dihydroxyvitamin D3 alters phospholipid metabolism in muscle
cells [131]. Finally, a group in Oxford has shown that 1,25-
dihydroxyvitamin D3 affects the synthesis of troponin C [132].
Troponin C plays a role in excitation coupling, and it is an E-F
hand-like protein in that it binds calcium in a manner similar to
calmodulin, myosin light chain kinase, and the vitamin D
calcium-binding proteins [132]. Thus, 1,25-dihydroxyvitamin
D3 has multiple effects on muscle. How these effects relate to
hypotonia is uncertain. Of course, the hypocalcemia found in
vitamin D deficiency results, on occasion, in seizure disorders.
DR. MADIAS: Let me extend the previous question. You
mentioned that vitamin D receptors and calcium-binding pro-
teins exist in many non-calcium-transporting tissues, such as
brain and pancreas. Is there any insight on what their role might
be in these tissues?
DR. KUMAR: I don't know what they are doing in brain. They
appear to be in very specific parts of the brain, particularly in
the Purkinje cells of the cerebellum. I have no good explanation
for what calcium-binding protein is doing in brain. Maybe these
cells require calcium at relatively high concentrations; possibly
calcium-binding protein affects intracellular calcium and free
calcium concentrations that are involved with the function of
those cells, That's just speculation.
DR. HARR!NGTON: I'd like to return to the quantitative
aspects of vitamin D metabolism. I understand from what you
said that side-chain oxidation accounts for 25% of the degrada-
tion of vitamin D. What accounts for the other 75%?
DR. KUMAR: If you give radioactive 1 ,25-dihydroxyvitamin
D3, eventually all of the tracer will appear in the feces and
urine. Almost 100% of it enters the feces and urine via excre-
tory metabolites [133, 1341. I would say that one-third of the
metabolism of 1,25-dihydroxyvitamin D3 would be accounted
for by the processes of side-chain oxidation and metabolism to
other hydroxylated forms. The other two-thirds would be
excreted by the liver, That is the major route of elimination of
l,25-dihydroxyvitamin D3. I neglected to mention that the
hepatic process is virtually non-saturable. You can give vast
amounts of I ,25-dihydroxyvitamin D3 and the same percentage
will be excreted no matter what the dose.
DR. BESS F. DAWSON-HUGHES (Division of Endocrinology,
New England Medical Center): There is some suggestion that
1 ,25-dihydroxyvitamin D3 affects calcium metabolism through
several mechanisms other than the stimulation of active trans-
port of calcium across the intestinal mucosa. One mechanism is
that it enhances the passive transport of calcium through the
paracellular shunt pathway. Another is that 1,25-dihydroxyvi-
tamin D3 has a trophic effect on the mucosa itself and increases
the absorptive surface area. Do you think either of these
mechanisms are important in humans?
DR. KUMAR: Let me try to answer the first question on the
trophic effects of I ,25-dihydroxyvitamin D3. It's very clear that
I ,25-dihydroxyvitamin D3 has a generalized tonic effect on
cells. A vitamin-D deficient animal is smaller than its vitamin
D-replete counterpart. If you give vitamin D to a vitamin
D-deficient animal, the rates of growth dramatically increase
within 24 hours [135]. Jim McCarthy, a colleague of mine,
examined the morphology of the intestine of vitamin D-deficient
chicks following the administration of 1 ,25-dihydroxyvitamin
D3. Rachitic animals had shrunken, atrophic intestinal Inucosa.
The administration of I ,25-dihydroxyvitamin D3 restored the
mucosa to normal within 12 hours [136]. Also, if you administer
I ,25-dihydroxyvitamin D3 to a rachitic animal, not only is there
an increase in amino acid uptake into calcium-binding protein,
there also is an increase in amino acid uptake into all proteins.
It just so happens that calcium-binding protein synthesis is
stimulated to a very large extent.
DR. DAWSON-HUGHES: Do you think 1,25-dihydroxyvitamin
D3 enhances calcium diffusion/absorption via a paracellular
shunt?
DR. KUMAR: I think that it doesn't. The effect of 1,25-
dihydroxyvitamin D3 is on active calcium transport that re-
quires energy. I don't believe that paracellular pathways are
energy dependent or are saturable. Clearly, vitamin D-induced
transport is active and saturable, which would suggest that it is
transcellular as opposed to paracellular.
DR. MADIAS: Is all vitamin D-dependent calcium absorption
mediated via synthesis of new protein?
DR. KUMAR: To a very large extent, yes. There is some
evidence that vitamin D or 1 ,25-dihydroxyvitamin D3 has
effects on membrane that increase the movement of calcium
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into the cells. There are non-genomic effects of 1,25 dihydroxy-
vitamin D. Norman and coworkers have performed experi-
ments suggesting that I ,25-dihydroxyvitamin D3 can increase
the absorption of calcium within 5 minutes in a perfused organ
system [137]. Protein synthesis couldn't play a role that
quickly. However, the intestines have to be from vitamin
D-replete animals. Recent excellent work shows that 1,25-
dihydroxyvitamin D3 increases the uptake of calcium into
hepatocytes and osteoblasts [1381. It is uncertain whether
transcellular calcium transport is increased in the absence of an
increase in protein synthesis. In patients with vitamin D-depen-
dency rickets type II, who have a defect in the l,25-dihydroxy-
vitamin D3 receptor, severe rickets occurs. Were non-genomic
events the only events important in the movement of calcium,
these individuals should not have rickets, but they have very
high circulating concentrations of 1 ,25-dihydroxyvitamin D3.
They require 500-600 g of 1,25 dihyroxyvitamin D3 to effect a
cure [1121. There's no question that there are effects of 1,25-
dihydroxyvitamin D3 on membrane that are direct and indepen-
dent of protein synthesis. I remain unconvinced that changes in
membrane structure play a major role in the movement of
calcium across the cell; changes in membrane structure may
play a role in the uptake of calcium into cells and organelles, but
whether that is equivalent to absorption of calcium is another
story.
DR. DAVID H. CAHAN (Division of Nephrology, Faulkner
Hospital, Jamaica Plain, Massachusetts): I'm curious about
the mechanism of vitamin D toxicity. Given the biologic inac-
tivity of 25-hydroxyvitamin D3 and the elegant negative feed-
back mechanisms on the 1-alpha hydroxylase system of the
kidney, what is known about 1,25 vitamin D3 levels in vitamin
D toxicity? What is the known mechanism of hypercalcemia?
DR. KUMAR: In vitamin D toxicity, 25-hydroxyvitamin D3
levels are very high, and 1,25 dihydroxyvitamin D3 concentra-
tions are either normal or marginally elevated because the
hypercalcemia switches off the 1-alpha hydroxylase enzyme.
Why then do you have increased calcium absorption? The
25-hydroxyvitamin D3 does bind to the 1,25 dihydroxyvitamin
D3 receptor, albeit with an affinity that is lower than that of
1,25-dihydroxyvitamin D3. The K0 of 1,25 dihydroxyvitamin D
for its receptor is approximately 10 10 or l0 M, whereas the
K0 of 25-hydroxyvitamin D3 for the receptor is lO_8 or iO M.
Typically, in vitamin D toxicity, you can have concentrations of
25-hydroxyvitamin D3 in the 200—300 ng/ml range, whereas the
1 ,25-dihydroxyvitamin D3 concentration under normal circum-
stances is only 30—50 pglml. It's feasible that if you have a three-
or fivefold increase in 25-hydroxyvitamin D3 concentrations
there might be sufficient 25-hydroxyvitamin D3 to bind with the
receptor to activate events that would cause more calcium
absorption.
The second explanation is one that we postulated some time
ago. We demonstrated that if you administer pharmacologic
amounts of 25-hydroxyvitamin D3 to animals, you could detect
significant amounts of 5,6-trans 25-hydroxyvitamin D3 in the
sera of such animals [139]. Cis-trans isomerization of the triene
structure will place the 3-beta hydroxyl group in the position of
the 1-alpha hydroxy group; the increased affinity of the 5,6
trans-25-hydroxyvitamin D3 molecule for the receptor could
activate hormonal events that would normally be brought about
by 1,25-dihydroxyvitamin D3. Those are the two explanations.
DR. HARRINGTON: It is apparent from the data you presented
that there is an efficient degradative pathway for vitamin D.
Given those data, how much extra vitamin D could one eat yet
still metabolize it rapidly enough to avoid toxicity?
DR. KUMAR: That's difficult to answer in precise quantatitive
terms. The hepatic excretion of 25-hydroxyvitamin D3 is much
slower than that of I ,25-dihydroxyvitamin D3. It's in the range
of 2% to 3% versus 25% to 30%. Clements had a paper in the
Lancet demonstrating that [1401. In terms of how much will
have a toxic effect, it depends in large part on stores. If one has
large stores and takes a modest amount of vitamin D, hyper-
calcemia could result, whereas someone with marginal stores
would be able to put a lot of it away and not have problems. I
can't give you a precise answer, but those are some things you
might want to consider.
DR. MADIAS: Have all these advances given us any new
insights on the mechanism of idiopathic hypercalciuria? Do we
know whether hydrochlorothiazide induces calcium-binding
proteins in the kidney?
DR. KUMAR: In renal leak hypercalciuria, the negative cal-
cium balance results in slightly higher 1 ,25-dihydroxyvitamin
D3 levels. In the patients with absorptive hypercalciuria, there
is supposed to be some other factor that increases 1,25-
dihydroxyvitamin D3 concentrations, perhaps persistent decre-
ments in phosphorus. Does hydrochiorothiazide directly induce
calcium binding protein? I have no knowledge of it doing so.
DR. MADIAS: Do we know how vitamin D increases calcium
mobilization from bone?
DR. KUMAR: It does so by increasing the activity of osteo-
clasts. Whether 1 ,25-dihydroxyvitamin D3 signals osteoclasts
directly or whether it does so via osteoblasts remains to be
determined. I believe that in physiologic circumstances, bone
resorption is not stimulated to a significant extent; after 1,25
dihydroxyvitamin D3 concentrations enter the higher part of the
normal range, bone resorption begins. I am not aware of
investigators who have been able to segregate cells such as
osteoblasts and osteoclasts and look for receptors for 1,25
dihydroxyvitamin D3 in the two different subpopulations as has
been done for PTH or estrogen.
Reprint requests to Dr. R. Kumar, Nephrology Research Unit,
Department of Medicine, Biochemistry and Molecular Biology Labo-
ratorv, Mayo Clinic and Foundation, Rochester, Minnesota 55905,
USA.
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